- Scheme Category:
- Equity Scheme >
NAV: ₹ ↓ -0.22%
NAV chart
SMA (Simple Moving Average)
- 50 SMA
- 100 SMA
- 200 SMA
- 400 SMA
Returns
CAGR returns till date
CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 11 September, 2026| Name | YTD | 1D | 1W | 1M | 3M | 1Y | 3Y | 5Y | 7Y | 10Y |
|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option | 12.09% | -0.22% | -0.58% | -1.4% | 6.1% | 10.69% | 18.57% | 13.65% | 22.83% | 15.57% |
| Nippon India Banking & Financial Services Fund - Direct Plan Growth Plan - Growth Option | -2.86% | 0.3% | -1.1% | -1.21% | 5.4% | 4.56% | 11.57% | 13.47% | 14.81% | 12.87% |
| Nippon India Power & Infra Fund - Direct Plan Growth Plan - Growth Option | 9.17% | -0.39% | -1.32% | -1.95% | 3.48% | 9.95% | 17.64% | 20.98% | 23.35% | 17.53% |
| DSP Healthcare Fund - Direct Plan - Growth | 16.51% | -0.24% | -0.89% | -0.83% | 8.82% | 15.26% | 21.74% | 15.34% | 25.7% | - |
| DSP Banking & Financial Services Fund - Direct - Growth | 5.28% | -0.28% | -2.01% | -1.43% | 8.88% | 15.23% | - | - | - | - |
| BANDHAN Infrastructure Fund-Direct Plan-Growth | 0.94% | -0.3% | -0.38% | -3.03% | 2.28% | -1.42% | 14.72% | 16.55% | 21.21% | 16.15% |
Discrete returns (yearly)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | -9.42% | 8.09% | 4.71% | 2.97% | 68.53% | 23.84% | -9.16% | 41.33% | 35.46% | -2.94% |
Discrete returns (monthly)
| Month | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | 0.9% | -1.24% | -4.66% | 5.31% | -4.85% | 6.03% | 2.37% | 5.46% | 2.71% | 2.06% |
Returns from spefic dates
| Description | CAGR returns from 18 Oct 2021 (Nifty 50 2021 high) | CAGR returns from 26 Sep 2024 (Nifty 50 2024 high) |
|---|---|---|
| Returns | 14.13% | 5.38% |
Portfolio
Asset allocation
| Equity | Debt | Realestate | Commodities | Cash & Equivalents |
|---|---|---|---|---|
| 97.32% | 0.00% (Arbitrage: 0.00%) | 0.00% | 0.00% | 2.68% |
Equity
| Name | Symbol / ISIN | Sector | Weight % | Other links |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA (INE044A01036) | Pharmaceuticals & Biotechnology | 13.31% | |
| Lupin Limited | LUPIN (INE326A01037) | Pharmaceuticals & Biotechnology | 7.25% | |
| Divi's Laboratories Limited | DIVISLAB (INE361B01024) | Pharmaceuticals & Biotechnology | 6.52% | |
| Cipla Limited | CIPLA (INE059A01026) | Pharmaceuticals & Biotechnology | 6.03% | |
| Apollo Hospitals Enterprise Limited | APOLLOHOSP (INE437A01024) | Healthcare Services | 5.30% | |
| Dr. Reddy's Laboratories Limited | DRREDDY (INE089A01031) | Pharmaceuticals & Biotechnology | 5.01% | |
| Mankind Pharma Limited | MANKIND (INE634S01028) | Pharmaceuticals & Biotechnology | 3.74% | |
| Sai Life Sciences Limited | SAILIFE (INE570L01029) | Pharmaceuticals & Biotechnology | 3.62% | |
| Ajanta Pharma Limited | AJANTPHARM (INE031B01049) | Pharmaceuticals & Biotechnology | 3.41% | |
| Max Healthcare Institute Limited | MAXHEALTH (INE027H01010) | Healthcare Services | 3.15% | |
| MedPlus Health Services Limited | MEDPLUS (INE804L01022) | Retailing | 2.69% | |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO (INE159A01016) | Pharmaceuticals & Biotechnology | 2.66% | |
| IPCA Laboratories Limited | IPCALAB (INE571A01038) | Pharmaceuticals & Biotechnology | 2.57% | |
| Thyrocare Technologies Limited | THYROCARE (INE594H01019) | Healthcare Services | 2.51% | |
| Vijaya Diagnostic Centre Limited | VIJAYA (INE043W01024) | Healthcare Services | 2.42% | |
| Abbott India Limited | ABBOTINDIA (INE358A01014) | Pharmaceuticals & Biotechnology | 2.24% | |
| Gland Pharma Limited | GLAND (INE068V01023) | Pharmaceuticals & Biotechnology | 2.16% | |
| Piramal Pharma Limited | PPLPHARMA (INE0DK501011) | Pharmaceuticals & Biotechnology | 2.09% | |
| Dr. Lal Path Labs Limited | LALPATHLAB (INE600L01024) | Healthcare Services | 2.05% | |
| Alkem Laboratories Limited | ALKEM (INE540L01014) | Pharmaceuticals & Biotechnology | 2.01% | |
| Narayana Hrudayalaya Limited | NH (INE410P01011) | Healthcare Services | 1.80% | |
| Pfizer Limited | PFIZER (INE182A01018) | Pharmaceuticals & Biotechnology | 1.65% | |
| Emcure Pharmaceuticals Limited | EMCURE (INE168P01015) | Pharmaceuticals & Biotechnology | 1.58% | |
| Aurobindo Pharma Limited | AUROPHARMA (INE406A01037) | Pharmaceuticals & Biotechnology | 1.54% | |
| Syngene International Limited | SYNGENE (INE398R01022) | Healthcare Services | 1.46% | |
| Fortis Healthcare Limited | FORTIS (INE061F01013) | Healthcare Services | 1.37% | |
| Sanofi India Limited | SANOFI (INE058A01010) | Pharmaceuticals & Biotechnology | 1.07% | |
| Suraksha Diagnostic Limited | SURAKSHA (INE877V01027) | Healthcare Services | 1.06% | |
| Sanofi Consumer Healthcare India Limited | SANOFICONR (INE0UOS01011) | Pharmaceuticals & Biotechnology | 1.06% | |
| Akums Drugs and Pharmaceuticals Limited | AKUMS (INE09XN01023) | Pharmaceuticals & Biotechnology | 1.00% | |
| Anthem Biosciences Limited | ANTHEM (INE0CZ201020) | Pharmaceuticals & Biotechnology | 0.92% | |
| Biocon Limited | BIOCON (INE376G01013) | Pharmaceuticals & Biotechnology | 0.92% | |
| AstraZeneca Pharma India Limited | ASTRAZEN (INE203A01020) | Pharmaceuticals & Biotechnology | 0.55% | |
| Indoco Remedies Limited | INDOCO (INE873D01024) | Pharmaceuticals & Biotechnology | 0.43% | |
| Concord Biotech Limited | CONCORDBIO (INE338H01029) | Pharmaceuticals & Biotechnology | 0.17% |
Portfolio data is as on date 31 July, 2026
NAV history
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history
| Date | NAV | % change |
|---|---|---|
| 11 September, 2026 | 638.3641 | -0.22% |
| 10 September, 2026 | 639.7674 | -0.56% |
| 9 September, 2026 | 643.4016 | -0.34% |
| 8 September, 2026 | 645.5743 | 0.31% |
| 7 September, 2026 | 643.5936 | 0.24% |
| 4 September, 2026 | 642.0816 | -0.57% |
| 3 September, 2026 | 645.7740 | -0.17% |
| 2 September, 2026 | 646.8638 | -0.11% |
| 1 September, 2026 | 647.5641 | -0.93% |
| 31 August, 2026 | 653.6135 | 0.61% |
| 28 August, 2026 | 649.6782 | 0.2% |
| 27 August, 2026 | 648.4050 | 0.13% |
| 26 August, 2026 | 647.5412 | 0.46% |
| 25 August, 2026 | 644.5844 | 0.45% |
| 24 August, 2026 | 641.6881 | -0.19% |
| 21 August, 2026 | 642.8931 | 0.09% |
| 20 August, 2026 | 642.2898 | 0.12% |
| 19 August, 2026 | 641.5364 | -0.28% |
| 18 August, 2026 | 643.3432 | 0.28% |
| 17 August, 2026 | 641.5439 | -0.46% |
| 14 August, 2026 | 644.4846 | -0.22% |
| 13 August, 2026 | 645.9200 | -0.22% |
| 12 August, 2026 | 647.3344 | -0.01% |
| 11 August, 2026 | 647.4211 | 0.75% |
| 10 August, 2026 | 642.5969 | 0.1% |
| 7 August, 2026 | 641.9838 | -0.01% |
| 6 August, 2026 | 642.0732 | 0.08% |
| 5 August, 2026 | 641.5674 | -0.2% |
| 4 August, 2026 | 642.8853 | -0.13% |
| 3 August, 2026 | 643.7372 |
FAQ (Frequently asked questions)
What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 638.3641 as on 11 September, 2026.What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 12.09% as on 11 September, 2026.What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 10.69% as on 11 September, 2026.What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 18.57% as on 11 September, 2026.What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 13.65% as on 11 September, 2026.What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 13.65% as on 11 September, 2026.What is LTCG (Long term capital gain) and STCG (Short term capital gain) tax for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is equity oriented mutual fund. Various capital gain taxes are applicable as below (Effective for redemption after July 23, 2024 and from FY 2024-25)Holding period Tax rate Less than 1 year (STCG) 20% More than 1 year (LTCG) Tax free upto Rs. 1.25 lakhs. 12.5% on rest amount.